Cargando…
World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA
The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 W...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/ https://www.ncbi.nlm.nih.gov/pubmed/24423618 http://dx.doi.org/10.4161/mabs.27437 |
_version_ | 1782304392756592640 |
---|---|
author | Klinguer-Hamour, Christine Strop, Pavel Shah, Dhaval K Ducry, Laurent Xu, April Beck, Alain |
author_facet | Klinguer-Hamour, Christine Strop, Pavel Shah, Dhaval K Ducry, Laurent Xu, April Beck, Alain |
author_sort | Klinguer-Hamour, Christine |
collection | PubMed |
description | The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 WADC San Francisco event was structured around plenary sessions with keynote speakers from AbbVie, Agensys, ImmunoGen, Immunomedics, Genentech, Pfizer and Seattle Genetics. Parallel tracks were also organized addressing ADC discovery, development and optimization of chemistry, manufacturing and control (CMC) issues. Discovery and process scientists, regulatory experts (US Food and Drug Administration), academics and clinicians were present, including representatives from biotechnology firms (Concortis, CytomX Therapeutics, Glykos, Evonik, Igenica, Innate Pharma, Mersana Therapeutics, Polytherics, Quanta Biodesign, Redwood Bioscience, Sutro Biopharma, SynAffix), pharmaceutical companies (Amgen, Genmab, Johnson and Johnson, MedImmune, Novartis, Progenics, Takeda) and contract research or manufacturing organizations (Baxter, Bayer, BSP Pharmaceuticals, Fujifilm/Diosynth, Lonza, Pierre Fabre Contract Manufacturing, Piramal, SAFC, SafeBridge). |
format | Online Article Text |
id | pubmed-3929441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-39294412014-03-05 World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA Klinguer-Hamour, Christine Strop, Pavel Shah, Dhaval K Ducry, Laurent Xu, April Beck, Alain MAbs Meeting Report The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 2010. Since 2011, two WADC are held every year in Frankfurt and San Francisco, respectively. The 2013 WADC San Francisco event was structured around plenary sessions with keynote speakers from AbbVie, Agensys, ImmunoGen, Immunomedics, Genentech, Pfizer and Seattle Genetics. Parallel tracks were also organized addressing ADC discovery, development and optimization of chemistry, manufacturing and control (CMC) issues. Discovery and process scientists, regulatory experts (US Food and Drug Administration), academics and clinicians were present, including representatives from biotechnology firms (Concortis, CytomX Therapeutics, Glykos, Evonik, Igenica, Innate Pharma, Mersana Therapeutics, Polytherics, Quanta Biodesign, Redwood Bioscience, Sutro Biopharma, SynAffix), pharmaceutical companies (Amgen, Genmab, Johnson and Johnson, MedImmune, Novartis, Progenics, Takeda) and contract research or manufacturing organizations (Baxter, Bayer, BSP Pharmaceuticals, Fujifilm/Diosynth, Lonza, Pierre Fabre Contract Manufacturing, Piramal, SAFC, SafeBridge). Landes Bioscience 2014-01-01 2013-12-06 /pmc/articles/PMC3929441/ /pubmed/24423618 http://dx.doi.org/10.4161/mabs.27437 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Meeting Report Klinguer-Hamour, Christine Strop, Pavel Shah, Dhaval K Ducry, Laurent Xu, April Beck, Alain World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA |
title | World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA |
title_full | World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA |
title_fullStr | World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA |
title_full_unstemmed | World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA |
title_short | World Antibody-Drug Conjugate Summit, October 15–16, 2013, San Francisco, CA |
title_sort | world antibody-drug conjugate summit, october 15–16, 2013, san francisco, ca |
topic | Meeting Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/ https://www.ncbi.nlm.nih.gov/pubmed/24423618 http://dx.doi.org/10.4161/mabs.27437 |
work_keys_str_mv | AT klinguerhamourchristine worldantibodydrugconjugatesummitoctober15162013sanfranciscoca AT stroppavel worldantibodydrugconjugatesummitoctober15162013sanfranciscoca AT shahdhavalk worldantibodydrugconjugatesummitoctober15162013sanfranciscoca AT ducrylaurent worldantibodydrugconjugatesummitoctober15162013sanfranciscoca AT xuapril worldantibodydrugconjugatesummitoctober15162013sanfranciscoca AT beckalain worldantibodydrugconjugatesummitoctober15162013sanfranciscoca |